Home > Insider Trading > Filing (0001567619-19-009182)

Filing Details

Accession Number:: 0001567619-19-009182
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-04-25 16:08:11
Reporting Period:: 2019-04-22

Accepted Time:: 2019-04-25 16:08:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595893	Turning Point Therapeutics Inc.	TPTX	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1583977	Cormorant Asset Management, Lp	200 Clarendon Street, 52Nd Floor Boston MA 02116		No	No	Yes	No
1599214	Bihua Chen	C/O Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor Boston MA 02116		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-04-22	400,000	$18.00	3,099,099	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (right to buy)	$2.19		2019-07-16	23,268	23,268	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2019-07-16	23,268	23,268	Indirect

Footnotes

Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP ("Fund II") and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, fund I, Fund II and the Account. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP, LLC ("GP I") and Cormorant Private Healthcare GP II, LLC ("GP II") serve as General Partner of the Master Fund, Fund I and Fund II, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP I and GP II.
Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Of the shares purchased on April 22, 2019, 367,840 were purchased for the Master Fund and 32,160 shares were purchased for the Account. As of April 22, 2019, the Master Fund held 1,351,749 shares, Fund I held 878,316 shares, Fund II held 653,145 shares, and the Account held 215,889 shares.
The stock options are currently exercisable. The Master Fund and Fund I may receive up to 10,516 and 12,516 shares, respectively, upon exercise of the stock options.